Oncotelic Therapeutics Inc (OTLC)
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for orphan oncology indications. Its pipeline includes antisense and small-molecule injectable candidates aimed at cancer treatment. Among the programs under development are OXi4503 for acute myeloid leukemia and myelodysplastic syndromes, and OT-101, an antisense therapy targeting TGF-ß2 that is in phase 3 trials for pancreatic cancer and glioblastoma and is also being studied for certain viral infections, including severe acute respiratory syndrome and coronavirus. The company is also advancing CA4P for advanced metastatic melanoma, AL-101 as an intranasal drug and delivery system for apomorphine-related uses, Artemisinin, and AI-based technologies and nanoparticle products intended to support development and commercialization efforts. Oncotelic Therapeutics is based in Agoura Hills, California, and its common stock trades on OTC Markets under the symbol OTLC.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-OTLC
|
$0.024
|
82.2% Upside
|
Bargain
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 18, 2026
|
30.4x
|
5.902 M
|
20.182 M
|
72.8%
|
51.3%
|
0.7
|
-0.6%
|
